BioWorld

April 14, 2003

View Archived Issues

XOMA Gets More Loan Money In Raptiva Deal With Genentech

Gearing up for an approval of the psoriasis drug Raptiva by year's end, Genentech Inc. and XOMA Ltd. have retooled their agreement, with the former financing the latter's development costs $80 million at a time. (BioWorld Today) Read More

Celltech Gains Clear Advantage In Bid For Oxford GlycoSciences

Read More

Hopes Of Multiplying Monkeys To Mimic Human Disease Models Fail, Like Reproductive People Cloning

Read More

Ribozyme Regains Herzyme Control After Elan Backs Out

Read More

Other News To Note

Read More

Appointments And Advancements

Read More